A randomized controlled trial of statin therapy effect on androgen status and erectile function in men with high and very high cardiovascular risk (TRISTAN): rationale and study protocol

Aim. To study the effect of different intensities of statin therapy on androgen status and erectile function in men aged 40-65 years with high and very high cardiovascular risk. Additionally, to assess the association between sex hormone levels, erectile function parameters, and traditional cardiovascular risk factors, arterial stiffness, and endothelial function in this patient category.

Material and methods. It is planned to conduct a prospective randomized controlled trial, including 150 male patients aged 40-65 years, undergoing routine preventive examinations in the clinic of Moscow State University, having a high and very high risk of CVD and meeting the inclusion criteria. Group 1 (n=75) will receive pitavastatin at a starting dose of 1 mg/day. Group 2 (n=75) will receive rosuvastatin 20 mg/day. After 3 months, the biochemical parameters will be monitored, and dose titration of pitavastatin to 2-4 mg/day and/or rosuvastatin to 40 mg/day will be performed if necessary. Patient recruitment to the study will occur over 9 months at a single research center. Patients will be monitored with an objective assessment of erectile function parameters, blood analysis (including androgen status), central arteries stiffness, and endothelial function for 6 months from the moment of activation. Follow-up visits are scheduled at 1, 3 and 6 months.

Results. The expected result of testing the research hypothesis is that statin therapy will not have a negative effect on androgen status and erectile function in men. Intensive statin therapy will have a greater positive effect on endothelial function, which may lead to an improvement in men’s erectile function.

Conclusion. The study was planned under the assumption that statin therapy would not have a negative effect on androgen status and erectile function in men aged 40-65 years. It is also suggested that the positive effect of statins on endothelial function and vascular stiffness may lead to an improvement in erectile function among men with high and very high cardiovascular risk. If the hypothesis is confirmed, the results obtained will help improve statin treatment adherence in male patients and, as a result, increase the effectiveness of prevention of cardiovascular events.

1. Drapkina OM, Drozdova LYu, Ipatov PV, et al. Follow-up monitoring of second health status group persons with high and very high cardiovascular risk. Guidelines. Cardiovascular Therapy and Prevention. 2024;23(6):4076. (In Russ.) DOI:10.15829/1728-8800-2024-4076.

2. Mamedov MN, Mitchenko EI, Serpitis P, et al. Updated European recommendations for the prevention of cardiovascular diseases. Analytical review. International Journal of Heart and Vascular Diseases. 2022;10(33):4-11. (In Russ.) DOI:10.24412/2311-1623-2022-33-4-1.

3. Mach F, Baigent C, Catapano A, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020;41(44):4255. DOI:10.1093/eurheartj/ehz826.

4. Najafov RN. Relationship between vascular age and atherosclerosis-related cardiovascular diseases. Russian Journal of Cardiology. 2021;26(6):4540. (In Russ.) DOI:10.15829/1560-4071-2021-4540.

5. Kontsevaya AV, Mukaneeva DK, Ignatieva VI, et al. Economics of cardiovascular prevention in the Russian Federation. Russian Journal of Cardiology. 2023;28(9):5521. (In Russ.) DOI:10.15829/1560-4071-2023-5521.

6. Martsevich SYu, Lukina YuV, Kutishenko NP, et al. Adherence to Statins Therapy of High and Very High Cardiovascular Risk Patients in Real Clinical Practice: Diagnostics and Possible Ways to Solve the Problem (According to the PRIORITY Observational Study). Rational Pharmacotherapy in Cardiology. 2018;14(6):891- 900. (In Russ.) DOI:10.20996/1819-6446-2018-14-6-891-900.

7. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. DOI:10.1056/NEJMoa0807646.

8. Taguchi I, Iimuro S, Iwata H, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation. 2018;137(19):1997-2009. DOI:10.1161/CIRCULATIONAHA.117.032615. Erratum in: Circulation. 2019;139(14):e836. DOI:10.1161/CIR.0000000000000676.

9. Liu C, Shen M, Tan WLW, et al. Statins improve endothelial function via suppression of epigenetic-driven EndM T. Nat Cardiovasc Res. 2023;2(5):467-85. DOI:10.1038/s44161-023-00267-1.

10. Satny M, Hubacek J, Vrablik M. Statins and Inflammation. Curr Atheroscler Rep. 2021;23(12):80. DOI:10.1007/s11883-021-00977-6.

11. Omolaoye TS, Halabi MO, Mubarak M, et al. Statins and Male Fertility: Is There a Cause for Concern? Toxics. 2022;10(10):627. DOI:10.3390/toxics10100627.

12. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57. DOI:10.1186/1741-7015-11-57.

13. Akorede BA, Hassan SA, Akhigbe RE. Penile erection and cardiovascular function: effects and pathophysiology. Aging Male. 2024:27(1);2336627. DOI:10.1080/13685538.2024.2336627.

14. Stamerra CА, Di Giosia P, Ferri C, et al. Statin therapy and sex hormones. Eur J Pharmacol. 2021;890:173745. DOI:10.1016/j.ejphar.2020.173745.

15. Pons-Rejraji H, Brugnon F, Sion B, et al. Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial. Reprod Biol Endocrinol. 2014;12:65. DOI:10.1186/1477-7827-12-65.

16. Cui Y, Zong H, Yan H, et al. The effect of statins on erectile dysfunction: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1367-75. DOI:10.1111/jsm.12497.

17. Oikonomou E, Siasos G, Zaromitidou M, et al. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. Atherosclerosis. 2015;238(2):159-64. DOI:10.1016/j.atherosclerosis.2014.12.014.

18. Nicholls S, Borgman M, Nissen S, et al. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011;27(6):1119-29. DOI:10.1185/03007995.2011.570746.

19. Hongo M, Tsutsui H, Mawatari E, et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ J. 2008;72(5):722-8. DOI:10.1253/circj.72.722.

20. Edgar R, Trip E, Wolterink G, et al. New methods for the monitoring of nocturnal erections. Int J Impot Res. 2022;34(1):1-7. DOI:10.1038/s41443-020-00365-9.

21. Wylie K, Steward D, Walters S. Does vibration offer any advantage over visual stimulation studies (VSS) in the assessment of erectile capacity? Int J Impot Res. 2001;13(6):329-37. DOI:10.1038/sj.ijir.3900781.

22. Kamalov AA, Matskeplishvili ST, Chaliy ME, et al. Vascular erectile dysfunction: a comprehensive approach to diagnosis. Experimental and Clinical Urology 2021;14(1):68-76 (In Russ.) DOI:10.29188/2222-8543-2021-14-1-68-76.

23. Huang Y, Liu W, Liu Y, et al. Effect of low-intensity extracorporeal shockwave therapy on nocturnal penile tumescence and rigidity and penile haemodynamics. Andrologia. 2020;52(10):e13745. DOI:10.1111/and.13745.

24. Chaliy ME, Ohobotov DA, Strigunov AA, et al. Normative parameters for monitoring of nocturnal penile tumescences: results of own observations and approbation of the developed normative criteria. Urologia. 2022;(5):39- 45. (In Russ.) DOI:10.18565/urologv.2022.5.39-45.

25. Kamalov AA, Matskeplishvili ST, Chaliy ME, et al. Assessing the influence of cardiovascular risk factors on the severity of erectile dysfunction: a multivariate statistical analysis. Urology Herald. 2022;10(1):15-31. (In Russ.) DOI:10.21886/2308-6424-2022-10-1-15-31.

26. Pushkar DYu, Rasner PI. IIEF Questionnaire. RMJ. 2013;21(18):11. (In Russ.) [Пушкарь Д.Ю., Раснер П.И. Опросник МИЭФ (IIEF). РМЖ. 2013;21(18):11].

27. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822-30. DOI:10.1016/s0090-4295(97)00238-0.

28. Corretti MC, Anderson TJ, Benjamin EJ, et al; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelialdependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257-65. DOI:10.1016/s0735-1097(01)01746-6. Erratum in: J Am Coll Cardiol. 2002;39(6):1082.